FDA Clears Lantern Pharma's Planned Phase 1b/2 Trial of LP-184 In Treatment-Resistant Lung Cancer Patients

benzinga.com/general/biotech/25/05/45345633/exclusive-fda-clears-lantern-pharmas-planned-phase-1b-2-trial-of-lp-184-in-treatment-resistant-lu

The U.S. Food and Drug Administration (FDA) on Monday cleared the amendment to Lantern Pharma Inc.’s (NASDAQ:LTRN) Investigational New Drug (IND) application for the Phase 1b/2 trial of LP-184 in a genomically defined patient population of non-small cell lung cancer (NSCLC).
The…

This story appeared on benzinga.com, 2025-05-12 12:31:40.
The Entire Business World on a Single Page. Free to Use →